Key Points {#FPar1}
==========

We compiled a comprehensive list of medications with documented effects on salivary gland function or symptoms that may assist practitioners assessing patients who complain of dry mouth while taking medications.The list may also prove useful in helping practitioners anticipate oral adverse effects and consider alternative medications.

Introduction {#Sec1}
============

Increased life expectancy, aging populations, and the association of these with polypharmacy have been intriguing topics over the last few decades. The World Health Statistics of 2014 published on the World Health Organization website reports a life expectancy of 55--87 years in its various constituent countries, with even the lower economy countries reporting rapid increases in life expectancy. However, with increased age comes a greater number of ailments, which in turn is indicative of a higher intake of medications.

Medications for the treatment of various diseases may also cause adverse effects, including those related to the oral cavity by their effects on the salivary glands. Apart from medications used to treat salivary gland disorders, other medications can also have the following adverse effects: salivary gland dysfunction (SGD), including salivary gland hypofunction (SGH) (an objectively measured decrease in salivation) or objective sialorrhea (an excessive secretion of saliva), xerostomia (subjective feeling of dry mouth), or subjective sialorrhea (feeling of having too much saliva). Medication-induced SGH and objective sialorrhea are collectively termed medication-induced salivary gland dysfunction (MISGD). The possible adverse effects associated with these disorders, especially SGH, include dental caries, dysgeusia, oral mucosal soreness, and oral candidiasis.

Current literature guiding clinicians in the prescribing of medications while considering the relevant adverse effects on salivary glands is very scarce. Most of the available literature attempting to list relevant drugs comprises a compendium based on manufacturers' drug profiles, narrative reviews, and case reports, or original research papers not containing a overall list of medications \[[@CR1]--[@CR10]\]. A systematic evidence-based list that identifies and lists medications that could objectively be associated with MISGD, xerostomia, or subjective sialorrhea is lacking. Hence, the MISGD group of the World Workshop on Oral Medicine VI (WWOM VI) aimed to review the current knowledge on this subject and compile a list of medications and their objective effects on salivary gland function, based on a high level of evidence and relevance.

Materials and Methods {#Sec2}
=====================

The MISGD group comprised five reviewers (AA, RJ, NN, YS, and AlV), six consultants (senior experts in fields related to MISGD: DA, CD, JE, AMP, GP, and ArV), one research librarian (RM), one group head (AW), and two supervisors on behalf of the WWOM VI Steering Committee (SBJ and ARK). This review addresses one of the MISGD topics covered by the group, an updated classification of medications reported to cause objective SGD. The research method was based on the policies and standards set forth by a task force for WWOM IV \[[@CR11]\] and by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement \[[@CR12]\], which was adapted to the current review.

Step 1: Scope Definition {#Sec3}
------------------------

The current review covered seven research questions, as follows:

Which medications have been reported to induce:SGD in humans?SGD in animals?xerostomia but *not* SGD?drooling but *not* SGD?xerostomia-related oral symptoms (but *not* SGD) other than excessive dryness/wetness?xerostomia but have *not been tested yet* for induction of SGD?drooling but have *not been tested yet* for induction of SGD?

Step 2: Search Term Selection {#Sec4}
-----------------------------

The following keywords and subject headings were selected for each research question:Medication/drugs/humans AND salivary gland dysfunction, xerostomia, dry mouth, reduced salivary flow rate, hyposalivation, sialorrhea, drooling.Medication/drugs/animals AND salivary gland dysfunction, reduced salivary flow rate, hyposalivation, drooling.Medication/drugs AND xerostomia, dry mouth, hyposalivation AND NOT salivary dysfunction.Medication/drugs AND drooling/sialorrhea/hypersalivation/ptyalism/increased salivary flow rate AND NOT salivary dysfunction.Medication/drugs AND salivary glands/saliva/xerostomia/dry mouth/hyposalivation AND NOT salivary gland dysfunction, oral sensory complaints.Medication/drugs AND salivary glands/saliva/xerostomia/dry mouth/hyposalivation AND NOT salivary gland dysfunction/assessment.Medication/drugs AND drooling/sialorrhea/hypersalivation/ptyalism AND NOT salivary gland dysfunction/assessment.

Step 3: Literature Search {#Sec5}
-------------------------

Our literature search was conducted, through June 2013, in the PubMed, Embase, and Web of Science databases based on our chosen keywords and subject headings where applicable and was not limited by publication date, publication type or language. In addition, group members were encouraged to submit articles of interest located through referral or hand searching. The search was completed by a hand search of the reference lists in the eligible papers. After duplicates were removed, 3867 records were retained for Step 4.

Step 4: Record Screening for Eligibility {#Sec6}
----------------------------------------

Each of the 3867 records was screened independently by the reviewers, who were supervised by the consultants. Papers were either retained for further analysis or excluded because they lacked relevance to any of the research questions; 269 papers relevant to the aforementioned topics were retained.

Step 5: Paper Selection for Type of Study, Relevance, and Level of Evidence {#Sec7}
---------------------------------------------------------------------------

This step started with calibration among the reviewers to ensure they applied similar standards in the performance of their reviews. Papers were then divided among the reviewers, who analyzed publication titles, abstracts, and the materials and methods sections for key parameters.

Medication General Inclusion and Exclusion Criteria {#Sec8}
---------------------------------------------------

Particular drugs for which MISGD has been reported were included.A group of drugs or a combination of two or more drugs without specifying the individual MISGD of each drug under the group or combination were excluded.Drugs reported to induce SGD or used in therapeutic aspects of SGD were excluded. Thus, parasympathomimetics (e.g., pilocarpine and cevimeline) and the anti-cholinesterases (e.g., physostigmine and neostigmine), which are used for stimulation of salivary flow in patients experiencing a dry mouth, were not included.Research drugs that were not yet marketed by the time of writing this manuscript, or that were subsequently removed from the market, were excluded.

Next, the retained articles were given scores based on the following assessments:The degree of relevance: level A (study dedicated to MISGD or xerostomia) or level B (study dedicated to adverse effects of medications).The strength of methodology provided in the paper: level 1 (typically meta-analyses, systematic reviews, and randomized controlled trials \[RCTs\]), level 2 (typically open-label trials, observational studies, animal studies, and epidemiological studies), or level 3 (typically narrative reviews and textbooks).

It should be noted that, in addition to the type of study (RCT, review, etc.), the quality of study design and performance were considered in assigning the level of evidence. Hence, articles were assigned scores in order of decreasing levels of evidence as follows: A1 \> B1 \> A2 \> B2 \> A3 \> B3.

Step 6: In-Depth Analysis {#Sec9}
-------------------------

In-depth analysis was based on expert interpretation of the evidence. Supervised by the group head and consultants CD and JE, reviewer RJ screened the remaining 332 selected publications by reading the full text. Another 63 papers were excluded for reasons such as assessing MISGD and xerostomia as an outcome of minor importance, leaving 269 articles for in-depth analysis. Figure [1](#Fig1){ref-type="fig"} depicts the steps of our work process and the distribution of the selected publications according to their score for level of evidence.Fig. 1Adapted PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the paper-selection process

As a consequence of step 6, we derived three lists of medications:56 medications with strong evidence that were quoted in articles with scores A1 or B1.50 medications with moderate evidence that were quoted in articles with scores A2 or B2 but not A1 or B1.48 medications with weak evidence that were quoted in articles with scores not higher than A3 or B3.

Results {#Sec10}
=======

Anatomical Therapeutic Chemical (ATC) Classification of Drugs {#Sec11}
-------------------------------------------------------------

The World Health Organization Collaborating Centre for Drug Statistics Methodology developed the Anatomical Therapeutic Chemical (ATC) classification system with defined daily doses (DDDs) as a system to classify therapeutic drugs. This system, which we also used, divides drugs into five different groups according to the organ or system on which they act and their chemical, pharmacological, and therapeutic properties. The first level contains 14 main groups according to anatomical site of action, with therapeutic subgroups (second level). The third and fourth levels are pharmacological and chemical subgroups, respectively, and the fifth level is the chemical compound itself.

We found that nine of the 14 groups in the first level contained medications reported with a strong or moderate level of evidence to be associated with SGD, xerostomia, or subjective sialorrhea: alimentary tract and metabolism, cardiovascular system, genitourinary system and sex hormones, anti-infectives for systemic use, anti-neoplastic and immunomodulating agents, musculoskeletal system, nervous system, respiratory system, and sensory organs. Among the 94 subgroups under the second level, 26 contain agents were reported to be associated with SGD, with 22 having strong evidence, namely drugs for functional gastrointestinal disorders, anti-emetics and anti-nauseants, anti-obesity preparations, anti-hypertensives, diuretics, beta-blocking agents, calcium channel blockers, urologicals, anti-neoplastic agents, muscle relaxants, drugs for the treatment of bone diseases, analgesics, anti-epileptics, anti-Parkinson drugs, psycholeptics, psychoanaleptics, other nervous system drugs, anti-muscarinic drugs for obstructive airway diseases, anti-histamines for systemic use, and ophthalmologicals. The third level is not included in Table [1](#Tab1){ref-type="table"} since it would add very little information. For the fourth level and its 882 subgroups described in the ATC/DDD system, 64 medication classes were found to be associated with SGD, and in 37 of these subgroups the association of SGD with the medications had stronger evidence. At the fifth level, 106 substances of the 4679 specified in the system were reported with a strong or moderate level of evidence to be associated with SGD. Of those, 56 drugs had a higher level of evidence of association with SGD (see Table [2](#Tab2){ref-type="table"}).Table 1Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with higher and moderate level of evidence, grouped according to their inclusion in first, second, fourth, and fifth ACT levelsFirst level, anatomical main groupSecond level, therapeutic subgroupFourth level, chemical subgroupFifth level, chemical substanceATC code**Alimentary tract and metabolismDrug for functional GI disorderSynthetic anti-cholinergics, quaternary ammonium compoundsPropanthelineA03AB05Belladonna alkaloids, tertiary aminesAtropineA03BA01**HyoscyamineA03BA03**Belladonna alkaloids, semisynthetic, quaternary ammonium compoundsScopolamine**/**hyoscineA03BB01Anti-emetics and anti-nauseantsOther anti-emeticsScopolamine**/**hyoscineA04AD01Anti-obesity preparations, excl. diet productsCentrally acting anti-obesity productsPhentermineA08AA01**DexfenfluramineA08AA04**SibutramineA08AA10**Peripherally acting anti-obesity productsOrlistatA08AB01**Serotonin--noradrenaline--dopamine reuptake inhibitor**TesofensineND**Cardiovascular system**Cardiac therapyAnti-arrhythmics, class IbMexiletineC01BB02**Anti-hypertensives**MethyldopaMethyldopaC02AB01**Imidazoline receptor agonistsClonidineC02AC01DiureticsThiazides, plainBendroflumethiazideC03AA01**Sulfonamides, plainFurosemideC03CA01Vasopressin antagonistsTolvaptanC03XA01**Beta-blocking agentsBeta-blocking agents, non-selectiveTimololC07AA06**Beta-blocking agents, selective MetoprololC07AB02AtenololC07AB03**Calcium channel blockers**Dihydropyridine derivativesIsradipineC08CA03**Phenylalkylamine derivativesVerapamilC08DA01**Agents acting on the renin-angiotensin systemACE inhibitors, plainEnalaprilC09AA02LisinoprilC09AA03**Genitourinary system and sex hormonesUrologicalsDrugs for urinary frequency and incontinenceOxybutyninG04BD04PropiverineG04BD06TolterodineG04BD07SolifenacinG04BD08**TrospiumG04BD09DarifenacinG04BD10FesoterodineG04BD11**ImidafenacinND**Alpha-adrenoreceptor antagonistsAlfuzosinG04CA01TerazosinG04CA03Anti-infectives for systemic useAnti-virals for systemic useProtease inhibitorsSaquinavirJ05AE01Nucleoside and nucleotide reverse transcriptase inhibitors DidanosineJ05AF02LamivudineJ05AF05Non-nucleoside reverse transcriptase inhibitors NevirapineJ05AG01EtravirineJ05AG04Other anti-viralsRaltegravirJ05AX08MaravirocJ05AX09**Anti-neoplastic and immunomodulating agentsAnti-neoplastic agentsMonoclonal antibodiesBevacizumabL01XC07Musculoskeletal systemMuscle relaxantsOther centrally acting agentsBaclofenM03BX01TizanidineM03BX02CyclobenzaprineM03BX08Drugs for treatment of bone diseasesBisphosphonatesAlendronateM05BA04Nervous system**AnestheticsOpioid anestheticsFentanylN01AH01**Analgesics**Natural opium alkaloidsMorphineN02AA01DihydrocodeineN02AA08Phenylpiperidine derivativesFentanylN02AB03**Oripavine derivativesBuprenorphineN02AE01Morphinan derivativesButorphanolN02AF01**Other opioidsTramadolN02AX02TapentadolN02AX06**Other anti-migraine preparationsClonidineN02CX02Anti-epileptics**Fatty acid derivativesSodium valproate/valproic acidN03AG01**Other anti-epilepticsGabapentinN03AX12**PregabalinN03AX16**Anti-Parkinson drugsDopamine agonistsRotigotineN04BC09PsycholepticsPhenothiazines with aliphatic side-chainChlorpromazineN05AA01Phenothiazines with piperazine structurePerphenazineN05AB03**Butyrophenone derivativesHaloperidolN05AD01**Indole derivatives**SertindoleN05AE03**ZiprasidoneN05AE04**LurasidoneN05AE05**Diazepines, oxazepines, thiazepines, and oxepinesLoxapineN05AH01ClozapineN05AH02OlanzapineN05AH03QuetiapineN05AH04**AsenapineN05AH05BenzamidesAmisulprideN05AL05**LithiumLithiumN05AN01Other anti-psychoticsRisperidoneN05AX08AripiprazoleN05AX12PaliperidoneN05AX13**Benzodiazepine derivatives (anxiolytics)ClobazamN05BA09**Benzodiazepine-related drugsZolpidemN05CF02**EszopicloneN05CF04ZopicloneN05CF01**Other hypnotics and sedativesScopolamine**/**hyoscineN05CM05**DexmedetomidineN05CM18**PsychoanalepticsNon-selective monoamine reuptake inhibitors**DesipramineN06AA01**ImipramineN06AA02AmitriptylineN06AA09NortriptylineN06AA10**DoxepinN06AA12DosulepinN06AA16**Selective serotonin reuptake inhibitorsFluoxetineN06AB03CitalopramN06AB04ParoxetineN06AB05SertralineN06AB06EscitalopramN06AB10Other anti-depressantsBupropionN06AX12VenlafaxineN06AX16ReboxetineN06AX18DuloxetineN06AX21**DesvenlafaxineN06AX23**VortioxetineN06AX26Centrally acting sympathomimeticsMethylphenidateN06BA04DexmethylphenidateN06BA11LisdexamfetamineN06BA12Other nervous system drugs**Drugs used in nicotine dependenceNicotineN07BA01Drugs used in alcohol dependenceNaltrexoneN07BB04**Drugs used in opioid dependenceBuprenorphineN07BC01NDNDDimebonND**TesofensineND**Respiratory system**Nasal preparationsAnti-allergic agents, excl. corticosteroidsAzelastineR01AC03**Drugs for obstructive airway diseasesAnti-cholinergicsTiotropiumR03BB04Anti-histamines for systemic useAminoalkyl ethersDoxylamineR06AA09**Piperazine derivatives CetirizineR06AE07LevocetirizineR06AE09Other anti-histamines for systemic use EbastineR06AX22DesloratadineR06AX27**Sensory organsOphthalmologicalsSympathomimetics in glaucoma therapyBrimonidineS01EA05Anti-cholinergicsAtropineS01FA01**Other anti-allergicsAzelastineS01GX07*ACE* angiotensin-converting enzyme, *ATC* Anatomical Therapeutic Chemical, *GI* gastrointestinal, *ND* not determined^a^Bold type indicates higher level of evidence Table 2Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with higher level of evidenceDrug nameATC codeMechanism and site of actionNumber of citations forSources per level of evidence (*n*)Total publications (*n*)ReferencesOral 'dryness'SialorrheaXerostomiaSGHSubjectiveObjectiveA1B1A2B2A3B3Alendronate (anti-bone-resorptive activity)M05BA04Bisphosphonate---inhibits osteoclastic bone resorption01001000001\[[@CR13]\]Amitriptyline (anti-depressant)N06AA09Non-selective 5-HT/NE reuptake inhibitor, anti-muscarinic51000103116\[[@CR14]--[@CR19]\]Aripiprazole (atypical anti-psychotic)N05AX12Dopamine stabilizer; partial dopamine (D2) and 5-HT1A agonist, 5-HT2A antagonist50000104005\[[@CR20]--[@CR24]\]Atropine (GI disorders/mydriatic)A03BA01, S01FA01Anti-muscarinic32000110114\[[@CR14], [@CR25]--[@CR27]\]Baclofen (skeletal muscle relaxant---centrally acting)M03BX01GABA agonist: reduces release of excitatory glutamate20000100001\[[@CR28]\]Bendroflumethiazide (weak diuretic)C03AA01Inhibits reabsorption of NaCl in distal tubule of nephron01001000001\[[@CR29]\]Bevacizumab (anti-neoplastic)L01XC07Monoclonal antibody: inhibits vascular proliferation and tumor growth10000100001\[[@CR30]\]Brimonidine (anti-glaucoma)S01EA05α~2~-Adrenergic agonist30000100113\[[@CR26], [@CR31], [@CR32]\]Buprenorphine (opioid-analgesic)N02AE01, N07BC01Mixed receptor actions; κ-opioid antagonist and partial µ-opioid agonist10000100001\[[@CR33]\]Bupropion (anti-depressant)N06AX12NE/dopamine reuptake inhibitor1200005030412\[[@CR34]--[@CR45]\]Butorphanol (opioid-analgesic)N02AF01QR05A90Mixed receptor actions; κ-agonist and µ-antagonist10000100001\[[@CR46]\]Chlorpromazine (anti-psychotic)N05AA01Antagonist to dopamine, 5-HT, histamine (H1), muscarinic and α~(1,2)~-adrenergic receptors20000100001\[[@CR47]\]Citalopram (anti-depressant)N06AB04Selective 5-HT reuptake inhibitor30000111003\[[@CR34], [@CR48], [@CR49]\]Clonidine (anti-hypertensive/anti-migraine)C02AC01, N02CX02α~2~-Adrenergic agonist01000100146\[[@CR14], [@CR50]--[@CR54]\]Clozapine (atypical anti-psychotic)N05AH02Dopamine antagonist, partial 5-HT and partial muscarinic (M1) agonist, muscarinic (M3) antagonist, and α~1~-adrenergic antagonist20073212109\[[@CR55]--[@CR57] ^a^, [@CR58]--[@CR61] [@CR62] ^a^, [@CR63]\]Cyclobenzaprine (skeletal muscle relaxant---centrally acting)M03BX08Histamine (H1) and muscarinic antagonist40000300003\[[@CR64]--[@CR66]\]Dexmethylphenidate (psychostimulant---ADHD)N06BA11Indirect sympathomimetic and NE/dopamine reuptake inhibitor10000100001\[[@CR67]\]Dimebon (anti-dementia)NDUnknown action---proposed histamine (H1) and 5-HT antagonist10000100001\[[@CR68]\]Doxylamine (hypnotic)R06AA09Anti-histamine; histamine (H1) and muscarinic antagonist10000100001\[[@CR69]\]Duloxetine (anti-depressant)N06AX215-HT/NE reuptake inhibitor19000010100819\[[@CR34], [@CR70]--[@CR87]\]Escitalopram (anti-depressant)N06AB10Selective 5-HT reuptake inhibitor40000102014\[[@CR34], [@CR84], [@CR88], [@CR89]\]Fluoxetine (anti-depressant)N06AB03Selective 5-HT reuptake inhibitor91000213039\[[@CR17], [@CR34], [@CR48], [@CR90]--[@CR95]\]Furosemide (strong diuretic)C03CA01Inhibits NaCl reabsorption in the thick ascending loop of Henle23002000103\[[@CR14], [@CR29], [@CR96]\]Gabapentin (anti-convulsant)N03AX12Proposed action: stimulates GABA synthesis and GABA release10000100001\[[@CR97]\]Imidafenacin (urological---reduces bladder activity)NDAnti-muscarinic10000100001\[[@CR98]\]Imipramine (anti-depressant)N06AA025-HT/NE-reuptake inhibitor, antagonist to histamine (H1), 5-HT, muscarinic and α~1~-adrenergic receptors20000100012\[[@CR99], [@CR100]\]Lisdexamfetamine (psychostimulant---ADHD)N06BA125-HT/NE reuptake inhibitor20000101002\[[@CR101], [@CR102]\]Lithium (anti-psychotic)N05AN01Mood stabilizer; inhibits dopamine/NE release and intracellular Ca^2+^ mobilization20000101114\[[@CR103], [@CR104]--[@CR106]\]Loxapine (anti-psychotic)N05AH01Dopamine/5-HT antagonist10000100001\[[@CR107]\]Methylphenidate (psychostimulant---ADHD)N06BA04Indirect sympathomimetic, release of dopamine, and NE/5-HT reuptake inhibitor50000202015\[[@CR37], [@CR108]--[@CR111]\]Nortriptyline (anti-depressant)N06AA10NE reuptake inhibitor, antagonist to histamine (H1), 5-HT, α~1~-adrenergics, and muscarinics20000100012\[[@CR97], [@CR112]\]Olanzapine (atypical anti-psychotic)N05AH03Antagonist to dopamine, 5-HT, histamine, muscarinics, and α~1~-adrenergics1000104150111\[[@CR20], [@CR56], [@CR113]--[@CR120] ^a^, [@CR121]\]Oxybutynin (urological---reduces bladder activity)G04BD04Anti-muscarinic20300070100421\[[@CR122]--[@CR142]\] (\[[@CR138]--[@CR140]\] are animal studies)Paliperidone (atypical anti-psychotic)N05AX13Antagonist to dopamine, 5-HT, α~(1,2)~ --adrenergics, and histamine20000100012\[[@CR143], [@CR144]\]Paroxetine (anti-depressant)N06AB055-HT reuptake inhibitor31000101013\[[@CR34], [@CR41], [@CR145]\]Perphenazine (anti-psychotic)N05AB03Antagonist to 5-HT, dopamine, histamine (H1), muscarinic, and α~1~-adrenergic receptors10000100001\[[@CR113]\]Phentermine (appetite suppressant)A08AA01Releases NE and to a lesser degree dopamine and 5-HT30000201003\[[@CR146]--[@CR148]\]Propantheline (anti-peristaltic/spasmolytic)A03AB05Anti-muscarinic21000200103\[[@CR14], [@CR129], [@CR133]\]Propiverine (urological---reduces bladder activityG04BD06Anti-muscarinic51000102126\[[@CR98], [@CR127], [@CR129], [@CR133], [@CR134], [@CR149] ^a^\]Quetiapine (atypical anti-psychotic)N05AH04Dopamine, 5-HT, α~(1,2)-~adrenergic, and histamine (H1) antagonist14020012010114\[[@CR103], [@CR113], [@CR116] [@CR144], [@CR150]--[@CR159]\]Reboxetine (anti-depressant)N06AX18NE reuptake inhibitor, anti-muscarinic50000102025\[[@CR85], [@CR160]--[@CR163]\]Risperidone (anti-psychotic)N05AX08Antagonist to dopamine, serotonin, histamine (H1), and α~1~,~2~ adrenergic receptors10100100012\[[@CR113], [@CR164]\]Rotigotine (anti-Parkinson)N04BC09Dopamine and 5-HT agonist, α~2~ adrenergic antagonist20000101002\[[@CR165], [@CR166]\]Scopolamine (anti-nauseant/sedative/GI disorders)A04AD01, N05CM05 A03BB01Muscarinic antagonist21000100113\[[@CR14], [@CR167], [@CR168]\]Sertraline (anti-depressant)N06AB065-HT reuptake inhibitor41000210014\[[@CR34], [@CR48], [@CR93], [@CR95]\]Sibutramine (anti-depressant)A08AA10Reuptake inhibitor of NE/5-HT/dopamine20000101002\[[@CR169], [@CR170]\]Solifenacin (urological---reduces bladder activity)G04BD08Anti-muscarinic920002054011\[[@CR133], [@CR134], [@CR137]--[@CR139], [@CR171]--[@CR176]\]Tesofensine (appetite suppressant)NDNE/5-HT/dopamine reuptake inhibitor10000100001\[[@CR177]\]Timolol (anti-glaucoma)C07AA06Non-selective β-adrenergic antagonist10000100001\[[@CR32]\]Tiotropium (anti-asthmatic)R03BB04Prevents bronchoconstriction, anti-muscarinic20000100012\[[@CR178], [@CR179]\]Tolterodine (urological---reduces bladder activity)G04BD07Anti-muscarinic19200041101319\[[@CR124], [@CR128], [@CR129], [@CR133]--[@CR135], [@CR138], [@CR142], [@CR180]--[@CR190] ^a^,[@CR191]\]Venlafaxine (anti-depressant)N06AX16NE/5-HT reuptake inhibitor80010107008\[[@CR17], [@CR34], [@CR52], [@CR89], [@CR192]--[@CR195]Verapamil (anti-hypertensive/anti-angina)C08DA01Calcium channel blocker---arterial vasodilator effects10000100001[@CR196]\]Vortioxetine (anti-depressant)N06AX265-HT reuptake inhibitor20000101002\[[@CR75], [@CR197]\]Ziprasidone (atypical anti-psychotic)N05AE045-HT, dopamine and α-adrenergic antagonist30000300003\[[@CR113], [@CR198], [@CR199]\]Zolpidem (hypnotic/sedative)N05CF02Agonist at the benzodiazepine site of the GABA~A~ receptor, enhancing the inhibitory effect of GABA20000200002\[[@CR200], [@CR201]\]*5-HT* 5-hydroxytryptamine (serotonin), *ADHD* attention-deficit/hyperactivity disorder, *ATC* Anatomical Therapeutic Chemical, *GABA* gamma-aminobutyric acid, *GI* gastrointestinal, *ND* not determined, *NE* norepinephrine, *SGH* salivary gland hypofunction^a^Animal studies

Medications with Strong Evidence {#Sec12}
--------------------------------

Fifty-six medications had strong evidence of interference with salivary gland function. These medications could be categorized into the following eight of the ten anatomical main groups (first level in the ATC system): alimentary tract and metabolism (A), cardiovascular system (C), genitourinary system and sex hormones (G), anti-neoplastic and immunomodulating agents (L), musculoskeletal system (M), nervous system (N), respiratory system (R), and sensory organs (S). More than half (36) belong to the ATC main category of nervous system, and the most cited in the literature are oxybutynin (21 papers), tolterodine (19), duloxetine (19), quetiapine (14), bupropion (12), olanzapine (11), solifenacin (11), clozapine (9), fluoxetine (9), and venlafaxine (8). Oxybutynin, tolterodine, and solifenacin are urologicals, while the remainder act on the nervous system. All medications on this list except alendronate, bendroflumethiazide, and clonidine have been reported to cause xerostomia, whereas SGH has been verified (via measurement of salivary flow rate) for alendronate, amitriptyline, atropine, bendroflumethiazide, clonidine, fluoxetine, furosemide, oxybutynin, paroxetine, propiverine, propiverine, scopolamine, sertraline, solifenacin, and tolterodine. Sialorrhea was found to be an adverse effect of clozapine, olanzapine, and venlafaxine, as objectively assessed excess salivation, and of quetiapine and risperidone, as a symptom. Animal experiments offer an explanation for the dual action (oral dryness and sialorrhea) of clozapine \[[@CR63], [@CR120]\]. Dysgeusia was reported after administration of amitriptyline, bevacizumab, buprenorphine, fluoxetine loxapine, quetiapine, and sertraline; dental caries were associated with chlorpromazine and lithium; oral candidiasis was associated with olanzapine; and burning mouth sensation was associated with amitriptyline (not in Table [2](#Tab2){ref-type="table"}). The properties of the various drugs listed in column 3 of Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} were primarily derived from the textbook *Goodman and Gilman's The Pharmacological Basis of Therapeutics* \[[@CR202]\].Table 3Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with moderate level of evidenceDrug name and functionATC codeMechanism and site of actionNumber of citations for:Sources per level of evidence (*n*)Total publications (*n*)ReferencesOral 'dryness'SialorrheaXerostomiaSGHSubjectiveObjectiveA2B2A3B3Amisulpride (atypical anti-psychotic)N05AL05Antagonist to dopamine and 5-HT100010012\[[@CR157], [@CR203] ^a^\]Asenapine (atypical anti-psychotic)N05AH05Antagonist to dopamine, 5-HT, histamine (H1) and α~(1,2)~ adrenergic receptors200001012\[[@CR115], [@CR204]\]Atenolol (anti-hypertensive/anti-arrhythmic)C07AB03β~1~-Adrenergic antagonist100001001\[[@CR205]\]Azelastine (anti-allergic)R01AC03,Histamine (H1) antagonist100001001\[[@CR206]\]Cetirizine (anti-allergic)R06AE07Histamine (H1) antagonist200001012\[[@CR206], [@CR207]\]Clobazam (anxiolytic/anti-convulsant)N05BA09Benzodiazepine---enhances the GABA effect on its receptors000101001\[[@CR208]\]Darifenacin (urological---reduces bladder activity)G04BD10Anti-muscarinic510012036\[[@CR133]--[@CR135], [@CR137], [@CR138], [@CR171]\]Desipramine (anti-depressant)N06AA01Preferential NE-reuptake inhibitor200011002\[[@CR91], [@CR209] ^a^\]Desloratadine (anti-allergic/anti-pruritic)R06AX27Histamine (H1)-antagonist, anti-muscarinic200001012\[[@CR210], [@CR211]\]Desvenlafaxine (anti-depressant)N06AX235-HT and NE reuptake inhibitor500003025\[[@CR52], [@CR212]--[@CR215]\]Dexfenfluramine (appetite suppressant)A08AA04Releases 5-HT200001012\[[@CR216], [@CR217]\]Dexmedetomidine (hypnotic sedative)N05CM18α~2~-Adrenergic agonist100001001\[[@CR218]\]Didanosine (anti-viral---HIV-1 therapy)J05AF02Nucleoside analog reverse transcriptase inhibitor100001001\[[@CR219]\]Dihydrocodeine (opioid-analgesic)N02AA08Weak agonist for the μ-opioid receptor100001001\[[@CR220]\]Dosulepin (anti-depressant)N06AA16Non-selective 5-HT/NE reuptake inhibitor, anti-muscarinic, anti-histamine (H1)100001001\[[@CR221]\]Doxepin (anti-depressant)N06AA12Non-selective 5-HT/NE reuptake inhibitor, anti-muscarinic, anti-histamine (H1), α~1~-adrenergic receptor antagonist200001001\[[@CR92]\]Ebastine (anti-allergic/anti-pruritus)R06AX22Histamine (H1) antagonist200003003\[[@CR222]--[@CR224]\]Enalapril (anti-hypertensive)C09AA02ACE inhibitor201001001\[[@CR205]\]Eszopiclone (hypnotic-sedative)N05CF04Enhances the GABA effect on its receptors300001023\[[@CR225]--[@CR227]\]Etravirine (anti-viral---HIV-1 therapy)J05AG04Non-nucleoside reverse transcriptase inhibitor100010001\[[@CR219]\]Fentanyl (opioid-analgesic)N01AH01, N02AB03Strong µ-opioid receptor agonist100001001\[[@CR218]\]Fesoterodine (urological - reduces bladder activity)G04BD11Anti-muscarinic400003014\[[@CR181], [@CR183], [@CR228]--[@CR230]\]Haloperidol (anti-psychotic)N05AD01Antagonist to dopamine, 5-HT, histamine (H1), muscarinic and α(~1,2~)adrenergic receptors201002002\[[@CR24], [@CR119]\]Hyoscyamine (anti-peristaltic/spasmolytic)A03BA03Anti-muscarinic100001001\[[@CR231]\]Isradipine (anti-hypertensive)C08CA03Calcium channel blocker---arterial vasodilator effects100001001\[[@CR205]\]Lamivudine (anti-viral---HIV, hepatitis B)J05AF05Nucleoside analog reverse transcriptase inhibitor100010001\[[@CR219]\]Levocetirizine (anti-allergic)R06AE09Histamine (H1) receptor antagonist100001001\[[@CR232]\]Lisinopril (anti-hypertensive)C09AA03ACE inhibitor100001001\[[@CR233]\]Lurasidone (anti-psychotic)N05AE055-HT/dopamine antagonist, α~2~-adrenerg receptor antagonist, partial 5-HT~(7)~-agonist100001001\[[@CR234]\]Maraviroc (anti-viral)J05AX09Prevents HIV from entering the cells100010001\[[@CR219]\]Methyldopa (anti-hypertensive)C02AB01False transmitter; synthesis of the less potent α-methyl-NE instead of NE201001012\[[@CR50], [@CR53]\]Metoprolol (anti-hypertensive/anti-arrhythmic)C07AB02β~1~-Adrenergic receptor antagonist110001102\[[@CR14], [@CR235]\]Mexiletine (anti-arrhythmic)C01BB02Sodium channel blocker100001001\[[@CR236]\]Morphine (opioid-analgesic)N02AA01Strong agonist on the µ-receptor200002002\[[@CR237], [@CR238]\]Naltrexone (treatment of alcoholism)N07BB04Opioid receptor antagonist100001001\[[@CR239]\]Nevirapine (anti-viral---HIV-1)J05AG01Non-nucleoside reverse transcriptase inhibitor100010001\[[@CR219]\]Nicotine (for smoking cessation)N07BA01Agonist to nicotinic receptors200002002\[[@CR240], [@CR241]\]Orlistat (anti-obesity)A08AB01Inhibits lipase, that breaks down dietary triglycerides100001001\[[@CR169]\]Pregabalin (anti-convulsant by non-GABAergic mechanisms)N03AX16Reduces transmitter release300001023\[[@CR242]--[@CR244]\]Raltegravir (anti-viral---HIV-1)J05AX08Prevents the integration of virus DNA into host chromosomes100010001\[[@CR219]\]Saquinavir (anti-viral)J05AE01HIV protease inhibitor100010001\[[@CR219]\]Sertindole (anti-psychotic)N05AE03Antagonist to dopamine, 5-HT and α~1~-adrenergic receptors200001012\[[@CR245], [@CR246]\]Sodium valproate (anti-convulsant)N03AG01Reduces the excitability of nerves by inhibiting the inflow of sodium ions100001001\[[@CR114]\]Tapentadol (opioid-analgesic)N02AX06Weak µ-opioid antagonist, and neuronal NE-reuptake inhibitor100001001\[[@CR247]\]Terazosin (urological---decreases urinary flow obstruction/anti- hypertensive)G04CA03α~1~-Adrenergic receptor antagonist100001001\[[@CR248]\]Tizanidine (anti-muscle-spasticity)M03BX02Releases GABA from spinal cord inhibitory interneurons, in addition weak α~2~-adrenergic agonist200020002\[[@CR28], [@CR249]\]Tolvaptan (diuretic)C03XA01Vasopressin V2 receptor antagonist preventing the action of the anti-diuretic hormone (ADH)100001001\[[@CR250]\]Tramadol (opioid-analgesic)N02AX02Weak µ-opioid receptor agonist and NE/ 5-HT reuptake inhibitor100001001\[[@CR237]\]Trospium (urological---reduces bladder activity)G04BD09Muscarinic receptor antagonist400002024\[[@CR128], [@CR132], [@CR133], [@CR137]\]Zopiclone (hypnotic)N05CF01Non-benzodiazepine---enhances the GABA effect on its receptors100001001\[[@CR251]\]*5-HT* 5-hydroxytryptamine (serotonin), *ACE* angiotensin-converting enzyme, *ATC* Anatomical Therapeutic Chemical, *GABA* gamma-aminobutyric acid, *NE* norepinephrine, *SGH* salivary gland hypofunction^a^Animal study

Medications with Moderate Evidence {#Sec13}
----------------------------------

Fifty medications had a moderate level of evidence of effects on salivary glands. These medications belonged to the following seven of the ten main anatomical groups (first level according to the ATC classification system): alimentary tract and metabolism, cardiovascular system, genitourinary system and sex hormones, anti-infectives for systemic use, nervous system, and respiratory system. Medications under the ATC category 'nervous system' were also the most commonly quoted medications in Table [3](#Tab3){ref-type="table"}. Xerostomia is an adverse effect of all the drugs listed in Table [3](#Tab3){ref-type="table"} except clobazam, whereas SGH was reported with darifenacin and metoprolol. Enalapril, haloperidol, and methyldopa were reported to cause a subjective feeling of sialorrhea. Objective sialorrhea was reported only with clobazam. Three medications (azelastine, enalapril, and fluvoxamine) were reportedly associated with dysgeusia, and one (haloperidol) was associated with dental caries (not in Table [3](#Tab3){ref-type="table"}).

Medications with Weak Evidence {#Sec14}
------------------------------

In total, 48 medications were reported to cause a range of adverse oral effects, such as xerostomia, SGH, sialorrhea, burning mouth sensation, dysgeusia, and dental caries (Table [4](#Tab4){ref-type="table"}).Table 4Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with weaker level of evidenceDrug nameNumber of citations for:Sources per level of evidence (*n*)Total publications (*n*)ReferencesOral 'dryness'SialorrheaXerostomiaSGHSubjectiveObjectiveA3B3Amiloride0100101\[[@CR14]\]Apraclonidine1000011\[[@CR26]\]Asimadoline1000011\[[@CR252]\]Atomoxetine1000011\[[@CR253]\]Biperiden1100101\[[@CR14]\]Chlorpheniramine1000011\[[@CR254]\]Chlorprothixene0100101\[[@CR14]\]Cisplatin1000011\[[@CR255]\]Clomipramine3000033\[[@CR90], [@CR95], [@CR145]\]Cyclothiazide0100101\[[@CR14]\]Cytisine1000011\[[@CR256]\]Diltiazem0100101\[[@CR14]\]Dimenhydrinate2000022\[[@CR167], [@CR254]\]Diphenhydramine1000011\[[@CR254]\]Disopyramide1000101\[[@CR14]\]Flupirtine1000011\[[@CR257]\]Granisetron1000011\[[@CR258]\]Guanfacine2000022\[[@CR53], [@CR259]\]Interleukin-2a0100101\[[@CR14]\]Ipratropium1000011\[[@CR260]\]Levomepromazine0100101\[[@CR14]\]Maprotiline1100101\[[@CR14]\]Mazindol1000011\[[@CR100]\]Melperone0100101\[[@CR14]\]Mepyramine1000011\[[@CR254]\]Metiamide0100101\[[@CR14]\]Milnacipran3000033\[[@CR85], [@CR261], [@CR262]\]Mirtazapine2000022\[[@CR18], [@CR263]\]Moclobemide1000011\[[@CR112]\]Modafinil2000022\[[@CR90], [@CR264]\]Mosapride1000011\[[@CR265]\]Moxifloxacin1000011\[[@CR266]\]Moxonidine3000033\[[@CR50], [@CR53], [@CR267]\]Nefazodone2000022\[[@CR268], [@CR269]\]Oxitropium1000011\[[@CR260]\]Perindopril1000011\[[@CR270]\]Pethidine0100101\[[@CR14]\]Phenelzine1000011\[[@CR113]\]Pheniramine0100011\[[@CR254]\]Promazine1000011\[[@CR157]\]Protriptyline2000022\[[@CR90], [@CR100]\]Pseudoephedrine1000011\[[@CR207]\]Rilmenidine2000022\[[@CR53], [@CR266]\]Selegiline1100112\[[@CR14], [@CR112]\]Thioridazine2100101\[[@CR14]\]Tianeptine1000101\[[@CR271]\]Triprolidine1000011\[[@CR254]\]Zimelidine0100101\[[@CR14]\]*SGH* salivary gland hypofunction

Discussion {#Sec15}
==========

Saliva plays a crucial role in maintaining the health and functioning of the mouth. Its functions include (1) maintaining a moist oral mucosa, (2) mucinous content acting as a lubricant in the mouth and oesophagus, (3) taste recognition by acting as a medium for suspension of tastants, (4) digestion of starches with the help of amylase, (5) acid buffering in the mouth and oesophagus mainly by bicarbonate, (6) protection of teeth from acids by being supersaturated with respect to tooth mineral and by contributing to the acquired enamel pellicle, (7) modulation of the oral microbiota with the help of anti-bacterial, anti-viral, and anti-fungal components, and (8) facilitating wound healing in the oral cavity \[[@CR272]\]. Medications may act on the central nervous system and/or at the neuroglandular junction, explaining the pathogenesis of MISDG. The secretory cells are supplied with muscarinic M1 and M3 receptors, α1- and β1-adrenergic receptors, and certain peptidergic receptors that are involved in the initiation of salivary secretion \[[@CR273]\]. It is therefore understandable that drugs that have antagonistic actions on the autonomic receptors but that are used to treat dysfunctions in the various effectors of the autonomic nervous system may also affect the functions of salivary glands and thus cause oral dryness. However, in some cases, the cause of oral dryness is not as evident, as with the bisphosphonate alendronate that was reported to reduce the unstimulated secretion of saliva \[[@CR13]\].

The anti-muscarinic drugs are well-known inducers of oral dryness as they prevent parasympathetic (cholinergic) innervation from activating the secretory cells. Surprisingly, clinical studies directly focusing on the secretion of saliva and the flagship of the anti-muscarinics, atropine, seem few. This is in contrast to numerous studies on animals, starting with the observations of the pioneers of salivary physiology in the 1870s.

The number of patients adversely affected by a specific drug, as well as the severity of the effect of this drug, are usually dose dependent. Figures for these parameters are not presented in the current study. Lack of saliva is often manifested as the sensation of dry mouth (xerostomia). A number of studies have suggested an association between the incidence of xerostomia and the number and dose of medications \[[@CR274]\]. That study also discussed secondary effects of MISGD in promoting caries or oral mucosal alterations.

Management of MISGD has mainly been based on a trial-and-error approach. Use of intraoral topical agents, such as a spray containing malic acid, sugar-free chewing gums or candy, saliva substitutes, or non-alcoholic mouthwashes to moisten or lubricate the mouth have served as the mainstay of treatment for patients with a dry mouth. Parasympathomimetic agents with potent muscarinic-stimulating properties, such as pilocarpine and cevimeline, and anti-cholinesterases, which reduce the rate of acetylcholine metabolism, have been used as systemic sialogogues. Although they increase salivation significantly, the adverse effect profile of these drugs upon systemic administration restricts their use in patients with MISGD. A local application of these categories of drugs onto the oral epithelium, with the aim of activating the underlying minor glands, may be an alternative approach. It is also necessary to ensure salivary gland functionality before administering these medications. Newer management methods include electrostimulation. Other management options for MISGD include possibly reducing the number of medications or the dosage or replacing them with medications or formulations with fewer xerogenic effects. Little evidence is available on this important topic; however, when dental treatment is needed, close communication between the dentist (who has to deal with the adverse effects) and the prescribing physician is warranted to obtain the best outcome for the patient \[[@CR275]\].

The present paper tries to fill the lacunae in regard to evidence-based listing of the effects of medications on salivary function as found in the current scientific literature. We conducted an extensive search of the literature related to MISGD, followed by meticulous scrutiny and analysis of the articles. However, it is still possible that a few medications were missed, and the lists in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} may not be exhaustive. Grading the evidence and relevance of each scientific article was a major issue. Consequently, the number of medications with strong or moderate evidence of being associated with SGD and xerostomia in our lists is much smaller than in other lists \[[@CR1]--[@CR6], [@CR9]\]. Moreover, some studies may have recorded salivary disorders only in an adverse effect table, and these would have been missed by our search. An additional issue is that our study does not include preparations containing more than one agent. However, any medication included in a mixed medication in these lists may have the potential to influence the salivary effects of the overall preparation. A further matter that warrants consideration is the possibility that certain drugs, while not exerting xerogenic effect when taken individually (and therefore not appearing in these lists), may do so as a result of drug--drug interaction if consumed together in a polypharmacy context \[[@CR7], [@CR8]\]. It should also be noted that, for some medications not included in this review because peer-reviewed publications on their salivary side effects were lacking, such side effects could have been mentioned on their monographs according to their manufacturer's controlled clinical trial. Finally, this article does not report the potency and frequency of salivary effects of the medications, as these data were rarely available.

The study suggests that medications acting on almost all systems of the body may also cause side effects related to the salivary system. At higher levels of the classification tree, the analysis seems to yield more specific details of the medications and their modes of action leading to SGD and xerostomia. Hence, the selection of an alternate drug with a similar effect on the desired system but fewer adverse salivary effects may be attempted based on this list. However, the possibility exists that other drugs that belong to the same level, especially at the fourth level of the ATC/DDD classification, may have a similar effect on salivary glands as the drug to be replaced.

Very few studies used objective measurements of salivary flow rates in the context of a medication adverse effect \[[@CR7], [@CR8], [@CR13], [@CR48]\]. Further, few articles seem to have correlated the results of such objective measurements with the subjective feelings of the patients receiving these drugs. Though animal studies have established a reduced salivary flow rate as an effect of medications, the subjective feeling of dryness (xerostomia) obviously cannot be registered in animals; hence, the relationship between changes in salivary flow rate and subjective feelings of dryness/drooling has been ambiguous \[[@CR104], [@CR120], [@CR138]--[@CR140], [@CR148]\].

It has been reported that xerostomia in healthy subjects is not experienced until the unstimulated flow rate of whole saliva has been reduced to 40--50% of normal \[[@CR27]\]. Furthermore, whether changes in the composition of the salivary secretion can also affect the subjective feelings of the patient remains to be clarified. However, the main difficulty encountered was the rarity of studies in which salivary flow rate or composition was actually measured before and after patients were prescribed medication. Moreover, baseline data were available for virtually no patients regarding their unstimulated saliva flow rates before they require medications. It seems to be only in Sweden that dental students are taught to measure the salivary flow rates of their patients to provide baseline values for any subsequent salivary problems that may develop. We suggest this is a valuable approach that should also be introduced in other countries.

Medications were also reported to cause other oral adverse effects. Aliko et al. \[[@CR274]\] point out that although independent reports relate a burning sensation of the oral mucosa and/or dysgeusia with MISGD, the relationship has not been established objectively. A few articles (albeit of moderate or weak level of evidence) mention that candidiasis and dental caries are associated with the use of certain drugs. None of these studies has tested the relationship between the pharmacokinetics of the drug, its effect on salivary glands, and other oral adverse effects reported \[[@CR274]\]. Dawes et al. \[[@CR272]\] reported that constituents of saliva have anti-fungal, anti-viral, and anti-bacterial properties, which indicates the role of saliva in controlling the oral microbiota and correlates SGH with occurrence of oral candidiasis. The relationship between SGH, dental caries, and oral candidiasis is well known and established. However, the same has not been tested in the context of MISGD in the current literature.

The present paper may help clinicians and researchers consider whether the medications they prescribe or investigate may lead to SGD or xerostomia. A few scenarios follow:A clinician needs to evaluate which drugs from the medication list of his/her patient have potential adverse salivary effects. The clinician may take the following steps:(i)Search in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} for the medications by alphabetical order.(ii)If the medications are not found, there is probably no published evidence for a salivary adverse effect.(iii)If found and they wish to know more about the medication type, they can search Table [1](#Tab1){ref-type="table"} using the ATC code(s) found in column 2 of Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. These codes are in the last column of Table [1](#Tab1){ref-type="table"} in alphabetical and numerical order.Before prescribing a medication, a clinician wishes to assess its potential salivary adverse effects. The above decision tree is also recommended in this situation.A treated patient complains of salivary symptoms but the clinician cannot find any of the medications in Tables [2](#Tab2){ref-type="table"} or Table [3](#Tab3){ref-type="table"}. However, it is plausible that additional medications not included in these tables could also affect salivary glands if they belong to the same ATC category at any level. For example, the anti-obesity medications fenfluramine, amfepramone, mazindol, etilamfetamine, cathine, clobenzorex, mefenorex, and lorcaserin are all 'centrally acting anti-obesity products', ATC A08AA \[[@CR276]\], and may act similarly to dexfenfluramine, which belongs to the same category and appears in Table [3](#Tab3){ref-type="table"}. Such an association may provide an explanation for the patient's symptoms.A clinician needs to prescribe medication to a patient with Sjögren's syndrome or who has undergone radiotherapy to the head and neck area and wishes to avoid worsening the patient's xerostomia. If, for example, the required drug is a muscle relaxant, the clinician may search the ATC website \[[@CR277]\] under 'muscle relaxants' and then double check the subgroups and Table [1](#Tab1){ref-type="table"}. There, they will find that 'other centrally acting agents' may have salivary effects and thus choose a medication belonging to any of the other subgroups.A researcher wishes to know whether a certain type of medication has salivary effects and at what level of evidence.(i)The researcher may start searching Table [1](#Tab1){ref-type="table"} for the type of medication according to the anatomical site of action (first level), therapeutic effect (second level), chemical characteristic (fourth level), or generic name (fifth level).(ii)If no relevant category is found, there is probably no published evidence for adverse salivary effects of this drug type.(iii)If the drug type is found at any of the levels in bold text, one of the drugs at the fifth level belonging to the category may be searched for in Table [2](#Tab2){ref-type="table"}, where the medications are in alphabetical order and information is available, i.e., type and number of publications and references.(iv)If the drug type is found but not in bold text, the researcher may proceed as in (iii) above but in Table [3](#Tab3){ref-type="table"} instead of Table [2](#Tab2){ref-type="table"}.

Conclusions {#Sec16}
===========

Most investigators relied on the subjective opinion of the individuals or patients about whether they had too little or an excessive secretion of saliva. Thus, we conclude that further RCTs that include saliva collection are warranted for the assessment of potential salivary effects of many medications. Unstimulated and stimulated salivary flow rates should be measured before and at intervals after starting the drug. In addition, a record of changes in the patients' subjective feelings over time should also be kept. Ideally, studies should also aim to assess changes in salivary composition, since these may also relate to SGD.
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